Research outlook

Where colorectal cancer treatment is heading

Colorectal cancer · Updated Nov 15, 2026

Colorectal cancer is the third most common cancer in the US, with about 150,000 new cases a year, and it is rising in people under 50. Early cancers are treated with surgery, often with chemotherapy, and for rectal cancer with radiation. Treatment increasingly depends on tumor tests: MSI-high or dMMR tumors respond strongly to immunotherapy, and KRAS G12C, BRAF V600E and HER2 changes each have targeted drugs. Research is aimed at sparing people unneeded treatment using blood tests, and at the large majority of tumors (MSS) where immunotherapy has not worked well.

  1. Now

    Nov 2026

    Immunotherapy for dMMR tumors at every stageHappened 86.3% cancer-free at 3 years

    Atezolizumab plus chemo after surgery: 86.3% cancer-free at 3 years vs 76.2%. Dostarlimab alone cleared dMMR rectal cancers without surgery.

    86.3%: free of cancer at 3 years, vs 76.2% with FOLFOX alone.

    BRAF-targeted first treatmentHappened 30.3 months median survival

    Encorafenib, cetuximab and FOLFOX doubled median survival to 30.3 months vs 15.1 in BRAF V600E cancer.

    30.3: months median survival, vs 15.1 with standard care.

    Exercise and aspirin after surgeryHappened 80.3% cancer-free at 5 years

    A 3-year exercise program raised 5-year cancer-free survival to 80.3% vs 73.9%. Aspirin halved recurrence in PI3K-mutated cancers.

    80.3%: free of cancer at 5 years with exercise, vs 73.9%.

  2. 6 months

    by May 2027

    Adagrasib for KRAS G12CLikely

    KRYSTAL-10 (461 people) compares adagrasib plus cetuximab with chemotherapy as second treatment; its main follow-up ended January 2026.

    A first immunotherapy combination for MSSPossible 10.9 months median survival

    After STELLAR-303 extended survival (10.9 vs 9.4 months), zanzalintinib plus atezolizumab could be submitted for approval.

    10.9: months median survival, vs 9.4 with regorafenib.

  3. 12 months

    by Nov 2027

    Immunotherapy alone or with chemoPossible 72% without progression at 2 years

    The NCI COMMIT trial asks whether adding chemotherapy to atezolizumab helps dMMR metastatic disease; due June 2027.

    72%: without progression at 2 years with nivolumab plus ipilimumab, vs 14%.

    Preventing new polypsPossible

    SWOG PACES tests eflornithine and sulindac to prevent new polyps and cancers after early colon cancer; due September 2027.

  4. 3 years

    by late 2029

    Targeted first treatments for KRAS G12C and HER2Possible

    CodeBreaK 301 (sotorasib, due September 2028) and MOUNTAINEER-03 (tucatinib, due December 2027) test targeted drugs as first treatment.

    Amivantamab against cetuximabPossible 29% tumors shrank (early trial)

    J&J's OrigAMI-2 (1,000 people, due December 2028) and OrigAMI-3 (700 people, due December 2027) compare amivantamab with standard EGFR antibodies.

    29%: of left-sided tumors shrank in an early trial.

    Blood tests to guide chemo after surgeryPossible 87% recurrence-free if ctDNA-negative

    CIRCULATE-US (1,912 people, due March 2029) uses ctDNA to decide who needs chemotherapy after colon cancer surgery.

    87%: free of recurrence at 3 years if ctDNA-negative, vs 49% if positive.

  5. 5 years

    by late 2031

    PD-1/VEGF bispecifics for MSS cancerLong shot

    Ivonescimab (due May 2028), pumitamig and Pfizer’s PF-08634404 (both due February 2030) replace bevacizumab in first-line chemotherapy.

    Immunotherapy instead of surgeryPossible 92% recurrence-free at 2 years

    GSK's AZUR-2 (892 people, due March 2029) tests dostarlimab around surgery for dMMR colon cancer, building on cases where tumors disappeared.

    92%: free of recurrence at 2 years.

Happened Likely Possible Long shot

The research paths

Maturing

Immunotherapy for dMMR tumors

86.3% cancer-free at 3 years
Details and 2 trialsHide
Heating up

Targeted drugs by mutation

30.3 months median survival
Details and 4 trialsHide
Heating up

New antibodies for MSS cancer

10.9 months median survival
Details and 5 trialsHide
Active

Blood tests and life after treatment

80.3% cancer-free at 5 years
Details and 2 trialsHide

Borrowed from other cancers

From EGFR-mutant lung cancer

Amivantamab

Phase 3

An EGFR-MET bispecific antibody approved for lung cancer, now in two phase 3 colorectal trials.

From Lung cancer

Ivonescimab and pumitamig

Phase 3

PD-1 or PD-L1 plus VEGF bispecific antibodies first tested in lung cancer.

From HER2-positive breast cancer

Tucatinib

Phase 3

A HER2 pill approved for breast cancer and, with trastuzumab, for later-line HER2-positive colorectal cancer.

Open to join now

See every recruiting Colorectal cancer trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Jan 2026
Jun 2027
Sep 2027
Dec 2027
May 2028
Dec 2028
Mar 2029
Calderasib, KRAS G12C, first lineTargeted drugs by mutation
Mar 2029
ctDNA-guided chemo after surgery (CIRCULATE-US)Blood tests and life after treatment
Mar 2029
Pumitamig plus chemo, first lineNew antibodies for MSS cancer
Feb 2030
PF-08634404 plus chemo (Symbiotic-GI-03)New antibodies for MSS cancer
Feb 2030

What just happened

Aspirin fails after liver metastasis treatment

ASAC, Lancet Gastroenterology & Hepatology.

Amivantamab shrinks tumors in heavily treated disease

OrigAMI-1, JCO.

Atezolizumab plus FOLFOX cuts recurrence in dMMR stage III colon cancer

ATOMIC, NEJM.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Colorectal cancer trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.